Dyax, Sigma-Tau sales and marketing update

Dyax and Sigma-Tau's Defiante Farmaceutica S.A. affiliate added Taiwan, Singapore, South Korea and Latin America to a 2010 deal granting Defiante rights to hereditary angioedema (HAE) therapy Kalbitor in Europe, North Africa, the Middle East and Russia. The new territories exclude Mexico and the Caribbean. In January, the companies added Australia and New Zealand to the deal. Sigma-Tau is responsible for all regulatory and commercialization costs in the territories (see BioCentury, June 28, 2010 & Jan. 17, 2011). ...